APA (7th ed.) Citation

Keshav, S., Ungashe, S., Zheng, W., Belker, P., Wright, K., & Schall, T. (2007). Ccx282-B, an orally active inhibitor of chemokine receptor Ccr9, shows anti-inflammatory and clinical activity in the treatment of Crohn's disease.

Chicago Style (17th ed.) Citation

Keshav, S., S. Ungashe, W. Zheng, P. Belker, K. Wright, and T. Schall. Ccx282-B, an Orally Active Inhibitor of Chemokine Receptor Ccr9, Shows Anti-inflammatory and Clinical Activity in the Treatment of Crohn's Disease. 2007.

MLA (9th ed.) Citation

Keshav, S., et al. Ccx282-B, an Orally Active Inhibitor of Chemokine Receptor Ccr9, Shows Anti-inflammatory and Clinical Activity in the Treatment of Crohn's Disease. 2007.